The DOI matches its Crossref record.
Role of Endothelin-1 in the Active Constriction of Human Atherosclerotic Coronary Arteries
Abstract
Background—Atherosclerotic coronary arteries are prone to constriction but the underlying causes are incompletely understood. We tested the hypothesis that endothelin-1 (ET-1), a potent vasoconstrictor, contributes to the heightened tone of atherosclerotic human coronary arteries. Methods and Results—In 8 patients with coronary artery disease (CAD) and 8 patients with angiographically smooth coronary arteries (normal), we infused BQ-123, an antagonist of the ET A receptor, into a major coronary artery (infused artery) at 40 nmol/min for 60 minutes. The infused artery in the CAD patients contained a >50% stenosis. Using quantitative angiography, we compared the dilation of the infused artery with another, noninfused coronary artery. To estimate the magnitude of the contribution of ET-1 to coronary tone, we compared the dilation to BQ-123 with that elicited by intracoronary nitroglycerin (200 μg). BQ-123 induced significant dilation in the normal arteries (7.3% at 60 minutes,P<0.001 versus noninfused arteries) and a greater dilation in the CAD arteries (16.3% at 60 minutes,P<0.001 versus infused normal arteries). The dilation at stenoses was particularly pronounced (21.6% at 60 minutes,P<0.001 versus infused CAD arteries). Compared with the dilation from nitroglycerin, ET-1 contributed to 39% of the coronary tone in normal arteries, 74% of tone in CAD arteries, and 106% of tone at stenoses (P<0.01). Conclusions—ET-1 accounts for nearly all the resting tone in atherosclerotic coronary arteries, especially at stenoses. Inhibitors of ET-1, by relieving constriction, may significantly lessen the hemodynamic significance of coronary stenoses and thereby reduce myocardial ischemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Endothelial Function and Dysfunction: Testing and Clinical Relevance
Deanfield, J. E., Halcox, J. P., & Rabelink, T. J. (2007) · Circulation · doi:10.1161/circulationaha.106.652859 · Cited by 2,710
Role of Endothelial Dysfunction in Atherosclerosis
Davignon, J., & Ganz, P. (2004) · Circulation · doi:10.1161/01.cir.0000131515.03336.f8 · Cited by 2,513
Self-citationEndothelial Function: Cardiac Events
Lerman, A., & Zeiher, A. M. (2005) · Circulation · doi:10.1161/01.cir.0000153339.27064.14 · Cited by 1,096
Endothelial dysfunction and vascular disease - a 30th anniversary update
Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017) · Acta Physiologica · doi:10.1111/apha.12646 · Cited by 937
“…normal coronary arteries, BQ123 (ETA receptor antagonist) induces an increase in the diameter of the proximal segments (Kyriakides et al. 2000, Kinlay et al. 2001, MacCarthy et al. 2001), and in coronary patients, mixed ETA/ETB blockade also increases the diameter of coronary vessels with no…”
BackgroundDeanfield, J., Donald, A., Ferri, C., Giannattasio, C., Halcox, J., Halligan, S., Lerman, A., Mancia, G., Oliver, J. J., Pessina, A. C., et al. (2005) · Journal of Hypertension · doi:10.1097/00004872-200501000-00004 · Cited by 634
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease
BOHM, F., & PERNOW, J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.06.004 · Cited by 516
Oxidized LDL, LOX-1 and Atherosclerosis
Mitra, S., Goyal, T., & Mehta, J. L. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6341-5 · Cited by 300
Endothelin: 30 Years From Discovery to Therapy
Barton, M., & Yanagisawa, M. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12105 · Cited by 295
Endothelin-1 synthesis reduced by red wine
Corder, R., Douthwaite, J. A., Lees, D. M., Khan, N. Q., Viseu dos Santos, A. C., Wood, E. G., & Carrier, M. J. (2001) · Nature · doi:10.1038/414863a · Cited by 290
A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity
Polk, A., Vistisen, K., Vaage-Nilsen, M., & Nielsen, D. L. (2014) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-15-47 · Cited by 267
Mast Cells in Allergic and Inflammatory Diseases
Sismanopoulos, N., Delivanis, D.-A., Alysandratos, K.-D., Angelidou, A., Therianou, A., Kalogeromitros, D., & C. Theoharides, T. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800165997 · Cited by 87
Burg, M. M., Meadows, J., Shimbo, D., Davidson, K. W., Schwartz, J. E., & Soufer, R. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000898 · Cited by 42
“ET-1, the most potent endogenous vasoconstricting agent, is secreted by endothelial cells and macrophages, and in the setting of coronary atherosclerosis is responsible to the greatest extent for coronary vasoconstriction.(35) ET-1 also acts synergistically with norepinephrine,(36) to accentuate dynamic vasoconstricti…”
Background
Metadata
- Authors
- Kinlay, S., Behrendt, D., Wainstein, M., Beltrame, J., Fang, J. C., Creager, M. A., Selwyn, A. P., & Ganz, P.
- Venue
- Circulation
- Published
- 2001-09-04
- Volume
- 104
- Issue
- 10
- Pages
- 1114-1118
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2124251979
- Cited by
- 172
- References
- 0
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.